AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22629353 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Bass technique
Number of subjects: 56
Study 22629353 — intervention group
Group type: COMPARATOR
Intervention: Control group (basics of tooth brushing)
Number of subjects: 56
Study 19641457 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 118
Study 19641457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 17136042 — intervention group
Group type: EXPERIMENTAL
Intervention: cholesterol-reducing diet (high in plant sterols 1.0 g/1000 kcal, soy protein 22.5 g/1000 kcal, viscous fibers 10 g/1000 kcal, almonds 23 g/1000 kcal)
Number of subjects: 66
Study 16446892 — intervention group
Group type: EXPERIMENTAL
Intervention: Epley Maneuver with post‐maneuver restrictions (23 patients)
Number of subjects: 50
Study 16446892 — intervention group
Group type: COMPARATOR
Intervention: Epley Maneuver without post‐maneuver restrictions (27 patients)
Number of subjects: 50
Study 11842353 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (passive range of motion exercise with gentle compression of both the upper and lower extremities, lasting 5-10 minutes each day, 5 days per week for 4 weeks)
Number of subjects: 24
Study 11842353 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 24
Study 10077139 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg b.i.d.
Number of subjects: 233
Study 10077139 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (BDP) 200 microg b.i.d.
Number of subjects: 233
Study 10077139 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 233
Study 7706804 — intervention group
Group type: EXPERIMENTAL
Intervention: Cidofovir alone at doses of 0.5, 1.0, 3.0, or 10.0 mg/kg/week (20 patients)
Number of subjects: 31
Study 7706804 — intervention group
Group type: COMPARATOR
Intervention: Cidofovir at 3.0, 5.0, or 7.5 mg/kg with concomitant oral probenecid, saline prehydration, extended dosing intervals, and drug interruption for proteinuria (19 patients)
Number of subjects: 31
Study 2037083 — intervention group
Group type: COMPARATOR
Intervention: Placebo medication
Number of subjects: 1969
Study 2037083 — intervention group
Group type: COMPARATOR
Intervention: Laboratory measurements (initial white cell count)
Number of subjects: 1969
Study 6183894 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% aluminium chloride hexahydrate in absolute alcohol
Number of subjects: 11
Study 6183894 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 11
Study 31453944 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + SE (static stretching after resistance training)
Number of subjects: 26
Study 31453944 — intervention group
Group type: COMPARATOR
Intervention: SE + RT (static stretching before resistance training)
Number of subjects: 26
Study 31453944 — intervention group
Group type: COMPARATOR
Intervention: RTSE (static stretching between resistance training)
Number of subjects: 26
Study 27876342 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofibrate 100 mg/d for 12 weeks
Number of subjects: 29
Study 27876342 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids 1800 mg/d for 12 weeks
Number of subjects: 29
Study 26359536 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking ≥4 cups/day of black tea
Number of subjects: 1325
Study 26359536 — intervention group
Group type: COMPARATOR
Intervention: Never drinking black tea
Number of subjects: 1325
Study 24192428 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher Kt/V
Number of subjects: 1825
Study 24192428 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dialyzer mass transfer-area coefficient for urea
Number of subjects: 1825
Study 24192428 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate of urea removal
Number of subjects: 1825
Study 21438784 — intervention group
Group type: EXPERIMENTAL
Intervention: Du-14 acupuncture
Number of subjects: 90
Study 21438784 — intervention group
Group type: EXPERIMENTAL
Intervention: Li-11 acupuncture
Number of subjects: 90
Study 21438784 — intervention group
Group type: EXPERIMENTAL
Intervention: St-36 acupuncture
Number of subjects: 90
Study 21438784 — intervention group
Group type: EXPERIMENTAL
Intervention: Sp-6 acupuncture
Number of subjects: 90
Study 21438784 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 90
Study 19122976 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 77
Study 19122976 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 77
Study 17694045 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinued warfarin (group 1)
Number of subjects: 214
Study 17694045 — intervention group
Group type: EXPERIMENTAL
Intervention: Suturing and discontinued warfarin (group 3)
Number of subjects: 214
Study 17694045 — intervention group
Group type: COMPARATOR
Intervention: Continued warfarin (group 2)
Number of subjects: 214
Study 17694045 — intervention group
Group type: COMPARATOR
Intervention: Suturing and continued warfarin (group 4)
Number of subjects: 214
Study 15369533 — intervention group
Group type: EXPERIMENTAL
Intervention: Labeling the correct color before responding (Experiment 2)
Number of subjects: 0
Study 15369533 — intervention group
Group type: EXPERIMENTAL
Intervention: Pointing to the large card (Experiment 3)
Number of subjects: 0
Study 15369533 — intervention group
Group type: COMPARATOR
Intervention: Decreasing affective salience of stimuli (colored beads vs. Smarties) (Experiment 3)
Number of subjects: 0
Study 10994916 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclists (C) at 100 W
Number of subjects: 31
Study 10994916 — intervention group
Group type: EXPERIMENTAL
Intervention: Runners (R) at 100 W
Number of subjects: 31
Study 10994916 — intervention group
Group type: EXPERIMENTAL
Intervention: Less-trained noncyclists (LT) at 75 W
Number of subjects: 31
Study 10994916 — intervention group
Group type: EXPERIMENTAL
Intervention: Less-trained noncyclists (LT) at 100 W
Number of subjects: 31
Study 10994916 — intervention group
Group type: EXPERIMENTAL
Intervention: Less-trained noncyclists (LT) at 150 W
Number of subjects: 31
Study 10994916 — intervention group
Group type: COMPARATOR
Intervention: Cyclists (C)
Number of subjects: 31
Study 10994916 — intervention group
Group type: COMPARATOR
Intervention: All groups (C, R, LT)
Number of subjects: 31
Study 9298081 — intervention group
Group type: EXPERIMENTAL
Intervention: Full intervention (computer-generated reminders promoting physician referral for mammography)
Number of subjects: 1225
Study 9298081 — intervention group
Group type: COMPARATOR
Intervention: Limited intervention (out-of-pocket mammography cost eliminated)
Number of subjects: 1225
Study 10146804 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol reduction programs
Number of subjects: 587
Study 4072339 — intervention group
Group type: EXPERIMENTAL
Intervention: Mnemonic device (method of loci)
Number of subjects: 48
Study 4072339 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 48
Study 31888670 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-marker diagnostic model (IDH1, SHOX2, PTGER4)
Number of subjects: 221
Study 31888670 — intervention group
Group type: COMPARATOR
Intervention: 2-marker model
Number of subjects: 221
Study 30077809 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbicort® pMDI 160/4.5 μg/actuation (2 actuations) with AeroChamber Plus® Flow‐Vu® spacer
Number of subjects: 50
Study 30077809 — intervention group
Group type: COMPARATOR
Intervention: Symbicort® pMDI 160/4.5 μg/actuation (2 actuations) without spacer
Number of subjects: 50
Study 30077809 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro study with AeroChamber Plus® Flow‐Vu® spacer
Number of subjects: 50
Study 30077809 — intervention group
Group type: COMPARATOR
Intervention: In vitro study without spacer
Number of subjects: 50
Study 27050796 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch from ticagrelor to clopidogrel
Number of subjects: 586
Study 24674663 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16/18/31/45 AS04 vaccine containing 20/20/10/10 μg VLPs
Number of subjects: 0
Study 24674663 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16/18/33/58 AS04 vaccine containing 20/20/20/20 μg VLPs
Number of subjects: 0
Study 24674663 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetravalent AS04 vaccines
Number of subjects: 0
Study 24674663 — intervention group
Group type: COMPARATOR
Intervention: Control (licensed HPV-16/18 AS04-adjuvanted vaccine)
Number of subjects: 0
Study 24674663 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetravalent vaccines with additional VLPs
Number of subjects: 0
Study 22451195 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX/FOLFIRI sequential chemotherapy
Number of subjects: 0
Study 20882929 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted vest (4-5 kg for 2 weeks, 8-10 kg for 4 weeks)
Number of subjects: 43
Study 20882929 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vest)
Number of subjects: 43
Study 19035721 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nicardipine (5-15 mg/hour)
Number of subjects: 30
Study 16175758 — intervention group
Group type: EXPERIMENTAL
Intervention: Life Goals Program (collaborative care model)
Number of subjects: 0
Study 14512476 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 301
Study 14512476 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol plus promethazine
Number of subjects: 301
Study 10713577 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholinesterase inhibitors (ChIs)
Number of subjects: 0
Study 10713577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9239913 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg oestradiol valerate and 2.5 mg medroxyprogesterone acetate
Number of subjects: 40
Study 9239913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 1499248 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release varnish containing chlorhexidine
Number of subjects: 7
Study 1499248 — intervention group
Group type: COMPARATOR
Intervention: Placebo varnish
Number of subjects: 7
Study 761675 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestasert (UPS)
Number of subjects: 326
Study 761675 — intervention group
Group type: EXPERIMENTAL
Intervention: Nova-T
Number of subjects: 326
Study 761675 — intervention group
Group type: COMPARATOR
Intervention: Both IUDs
Number of subjects: 326
Study 30291370 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical atorvastatin 1%
Number of subjects: 70
Study 27617502 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate (27 mg per day for 8 weeks)
Number of subjects: 99
Study 27617502 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (320 mg per day for 8 weeks)
Number of subjects: 99
Study 27617502 — intervention group
Group type: COMPARATOR
Intervention: Placebo (daily for 8 weeks)
Number of subjects: 99
Study 25808783 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety sensitivity
Number of subjects: 396
Study 23007491 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilatory Threshold (VT)
Number of subjects: 18
Study 23007491 — intervention group
Group type: COMPARATOR
Intervention: Equivocal Stage (EQ)
Number of subjects: 18
Study 23007491 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory Compensation Threshold (RCT)
Number of subjects: 18
Study 23007491 — intervention group
Group type: COMPARATOR
Intervention: Negative Stage (NEG)
Number of subjects: 18
Study 21372038 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulforaphane-rich beverage (SFR)
Number of subjects: 50
Study 21372038 — intervention group
Group type: COMPARATOR
Intervention: Glucoraphanin-rich beverage (GRR)
Number of subjects: 50
Study 19147689 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 0
Study 19147689 — intervention group
Group type: COMPARATOR
Intervention: Concomitant anthracycline therapy
Number of subjects: 0
Study 19147689 — intervention group
Group type: EXPERIMENTAL
Intervention: Reintroduction of trastuzumab after resolution of normal cardiac function
Number of subjects: 0
Study 17377117 — intervention group
Group type: EXPERIMENTAL
Intervention: Abduction group (arm in abduction)
Number of subjects: 0
Study 17377117 — intervention group
Group type: COMPARATOR
Intervention: Adduction group (arm in adduction)
Number of subjects: 0
Study 16332430 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) as an add-on treatment
Number of subjects: 35
Study 16332430 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LEV)
Number of subjects: 35
Study 14639483 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure bandage for 1 week followed by immediate mobilization
Number of subjects: 35
Study 14639483 — intervention group
Group type: COMPARATOR
Intervention: Ulnar gutter plaster cast for 3 weeks followed by mobilization
Number of subjects: 35
Study 10365896 — intervention group
Group type: EXPERIMENTAL
Intervention: TUBT (tablet-based 13C urea breath test)
Number of subjects: 134
Study 10365896 — intervention group
Group type: COMPARATOR
Intervention: SUBT (standard 13C urea breath test)
Number of subjects: 134
Study 7578166 — intervention group
Group type: EXPERIMENTAL
Intervention: simvastatin 10 mg daily
Number of subjects: 48
Study 7578166 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil 600 mg twice daily
Number of subjects: 48
Study 7578166 — intervention group
Group type: EXPERIMENTAL
Intervention: cholestyramine 4 gm twice daily
Number of subjects: 48
Study 2272022 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine (10 micrograms/kg subcutaneously with oral domperidone 10 mg)
Number of subjects: 9
Study 2272022 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sultopride (50 mg)
Number of subjects: 9
Study 2272022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 7000282 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education booklet describing the management of six common symptoms
Number of subjects: 0
Study 7000282 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 7000282 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education booklet
Number of subjects: 0
Study 29621885 — intervention group
Group type: EXPERIMENTAL
Intervention: Far-infrared garments
Number of subjects: 20
Study 27307483 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive extracorporeal circulation (MiECC)
Number of subjects: 60
Study 27307483 — intervention group
Group type: COMPARATOR
Intervention: Conventional cardiopulmonary bypass (cCPB)
Number of subjects: 60
Study 23972505 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.2% nitroglycerin ointment
Number of subjects: 60
Study 23972505 — intervention group
Group type: COMPARATOR
Intervention: Open partial lateral anal sphincterotomy
Number of subjects: 60
Study 22357861 — intervention group
Group type: EXPERIMENTAL
Intervention: Test and mask stimuli with distinct temporal frequencies; specific details on dosage and duration not applicable.
Number of subjects: 0
Study 22357861 — intervention group
Group type: EXPERIMENTAL
Intervention: Test and mask stimuli with equal contrast; specific details on dosage and duration not applicable.
Number of subjects: 0
Study 22357861 — intervention group
Group type: EXPERIMENTAL
Intervention: Divisive gain control models with 30 ms integration time; specific details on dosage and duration not applicable.
Number of subjects: 0
Study 22357861 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast normalization; specific details on dosage and duration not applicable.
Number of subjects: 0
Study 20705780 — intervention group
Group type: EXPERIMENTAL
Intervention: AutoFlow assist-controlled ventilation
Number of subjects: 42
Study 20705780 — intervention group
Group type: COMPARATOR
Intervention: Conventional assist-controlled ventilation
Number of subjects: 42
Study 18060342 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab therapy
Number of subjects: 10
Study 18060342 — intervention group
Group type: COMPARATOR
Intervention: Control (no infliximab therapy)
Number of subjects: 10
Study 15788330 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroprosthesis group (NESS Handmaster)
Number of subjects: 22
Study 15788330 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study 12495435 — intervention group
Group type: EXPERIMENTAL
Intervention: CCCT(1/4)
Number of subjects: 67
Study 12495435 — intervention group
Group type: EXPERIMENTAL
Intervention: CCCT(1)
Number of subjects: 67
Study 12495435 — intervention group
Group type: EXPERIMENTAL
Intervention: S1/S2
Number of subjects: 67
Study 12495435 — intervention group
Group type: EXPERIMENTAL
Intervention: T1/M1
Number of subjects: 67
Study 12495435 — intervention group
Group type: EXPERIMENTAL
Intervention: D/S
Number of subjects: 67
Study 10624430 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen (g. cyclopentolate 1% stat. and oc. chloramphenicol q.d.s. for 5 days)
Number of subjects: 74
Study 10624430 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard regimen followed by additional nightly ointment (Lacrilube) for 2 months
Number of subjects: 74
Study 8808540 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation (6 participants)
Number of subjects: 12
Study 8808540 — intervention group
Group type: COMPARATOR
Intervention: Control (non-meditating, 6 participants)
Number of subjects: 12
Study 2188826 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg daily (n = 68)
Number of subjects: 136
Study 2188826 — intervention group
Group type: COMPARATOR
Intervention: Sustained-release nifedipine 20 mg twice daily (n = 68)
Number of subjects: 136
Study 2188826 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine group
Number of subjects: 136
Study 2188826 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril group
Number of subjects: 136
Study 2188826 — intervention group
Group type: COMPARATOR
Intervention: Enalapril vs Nifedipine
Number of subjects: 136
Study 7198465 — intervention group
Group type: EXPERIMENTAL
Intervention: plafibride (1200 mg/d for 15 days)
Number of subjects: 90
Study 7198465 — intervention group
Group type: EXPERIMENTAL
Intervention: plafibride
Number of subjects: 90
Study 7198465 — intervention group
Group type: COMPARATOR
Intervention: clofibrate
Number of subjects: 90
Study 7198465 — intervention group
Group type: COMPARATOR
Intervention: acetylsalicylic acid (ASA)
Number of subjects: 90
Study 29511062 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab for 6 months
Number of subjects: 303
Study 27734563 — intervention group
Group type: EXPERIMENTAL
Intervention: AP-HR (artificial pancreas system connected to a heart rate monitor)
Number of subjects: 18
Study 27734563 — intervention group
Group type: COMPARATOR
Intervention: stdAP (unmodified artificial pancreas)
Number of subjects: 18
Study 25907488 — intervention group
Group type: EXPERIMENTAL
Intervention: Xinkeshu (12 capsules/d) on top of standard therapy
Number of subjects: 40
Study 25907488 — intervention group
Group type: COMPARATOR
Intervention: Placebo on top of standard therapy
Number of subjects: 40
Study 23868621 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal polyps (NPs) group (group 1)
Number of subjects: 60
Study 23868621 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 2) - patients with septal deviations and concha hypertrophies
Number of subjects: 60
Study 21836413 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy with half-dose verteporfin
Number of subjects: 34
Study 21836413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 19169191 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy (e.g., selective serotonin reuptake inhibitors)
Number of subjects: 0
Study 19169191 — intervention group
Group type: COMPARATOR
Intervention: Consensus guidelines on pharmacotherapy for PTSD
Number of subjects: 0
Study 17878474 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (60 Gy conventional irradiation)
Number of subjects: 1005
Study 17878474 — intervention group
Group type: COMPARATOR
Intervention: Wait-and-see
Number of subjects: 1005
Study 14755505 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC)
Number of subjects: 102
Study 11090571 — intervention group
Group type: EXPERIMENTAL
Intervention: CC (2 g/kg body wt of CHO in a 25.7% CHO beverage 30 min before and 2 g/kg of CHO in a 6.4% CHO solution throughout SS)
Number of subjects: 7
Study 11090571 — intervention group
Group type: EXPERIMENTAL
Intervention: PC (placebo 30 min before and 2 g/kg body wt of CHO in a 6.4% CHO solution throughout SS)
Number of subjects: 7
Study 11090571 — intervention group
Group type: COMPARATOR
Intervention: PP (placebo beverage before and during SS)
Number of subjects: 7
Study 11090571 — intervention group
Group type: EXPERIMENTAL
Intervention: CP (2 g/kg body wt of CHO in a 25.7% CHO beverage 30 min before and placebo throughout SS)
Number of subjects: 7
Study 9069692 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care (40-hour training program)
Number of subjects: 1078
Study 9069692 — intervention group
Group type: COMPARATOR
Intervention: Traditional pharmacy services
Number of subjects: 1078
Study 8417381 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy with fluorouracil
Number of subjects: 115
Study 8417381 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy without fluorouracil
Number of subjects: 115
Study 8417381 — intervention group
Group type: COMPARATOR
Intervention: Smoking cessation (quit more than 1 year before diagnosis)
Number of subjects: 115
Study 8417381 — intervention group
Group type: COMPARATOR
Intervention: Smoking cessation (quit less than 12 weeks before diagnosis)
Number of subjects: 115
Study 8417381 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking during radiation therapy
Number of subjects: 115
Study 3770045 — intervention group
Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum (2 mg/m2) every 3 weeks for a maximum of eight courses followed by DTIC (250 mg/m2 i.v. daily X 5) and Actinomycin D (1.5 mg/m2 on Day 1)
Number of subjects: 79
Study 3770045 — intervention group
Group type: COMPARATOR
Intervention: DTIC (250 mg/m2 i.v. daily X 5) and Actinomycin D (1.5 mg/m2 on Day 1)
Number of subjects: 79
Study 3770045 — intervention group
Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum followed by chemotherapy
Number of subjects: 79
Study 3770045 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 79